A Phase 1 Study of LY2127399 in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1 Study of LY2127399 in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Tabalumab (Primary) ; Bortezomib; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Feb 2016 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 19 Aug 2015 Planned End Date changed from 1 Dec 2015 to 1 Aug 2015, according to ClinicalTrials.gov record.
    • 15 Jul 2015 Planned End Date changed from 1 Oct 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top